Table 4 Toxicity and Clinical Events.

From: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

 

Men N = 294

Women N = 218

Overall N = 512

Chi squared test p-value

Grade ≥  3 heamatological toxicity (except anemia) - n (%)

65 (22.1)

87 (39.9)

152 (29.7)

<0.0001

Grade ≥ 3 leukopenia - n (%)

6 (2.0)

5 (2.3)

11 (2.1)

Grade ≥ 3 febrile neutropenia - n (%)

4 (1.4)

6 (2.8)

10 (2.0)

Grade ≥ 3 non-febrile neutropenia - n (%)

62 (21.1)

81 (37.2)

143 (27.9)

Grade ≥ 3 thrombocytopenia - n (%)

1 (0.3)

4 (1.8)

5 (1.0)

Grade ≥ 3 anemia - n (%)

1 (0.3)

1 (0.5)

2 (0.4)

Grade ≥ 3 gastrointestinal toxicity - n (%)

24 (8.2)

31 (14.2)

55 (10.7)

0.0286

Grade ≥ 3 diarrhea - n (%)

14 (4.8)

20 (9.2)

34 (6.6)

Grade ≥ 3 nausea - n (%)

6 (2.0)

8 (3.7)

14 (2.7)

Grade ≥ 3 vomiting - n (%)

5 (1.7)

6 (2.8)

11 (2.1)

Grade ≥ 3 stomatitis - n (%)

1 (0.3)

1 (0.5)

2 (0.4)

Grade ≥ 3 mucositis - n (%)

1 (0.3)

3 (1.4)

4 (0.8)

Grade ≥ 2 neurotoxicity - n (%)

72 (24.5)

61 (28.0)

133 (26.0)

0.3730

Grade ≥ 2 ototoxicity - n (%)

1 (0.3)

0 (0.0)

1 (0.2)

Grade ≥ 2 central neurotoxicity - n (%)

9 (3.1)

7 (3.2)

16 (3.1)

Grade ≥ 2 paresthesia/dysesthesia - n (%)

63 (21.4)

55 (25.2)

118 (23.0)

Relapse - n (%)

50 (17.0)

32 (14.7)

82 (16.0)

0.4776

Death - n (%)

45 (15.3)

26 (11.9)

71 (13.9)

0.2739

Relapse or death - n (%)

67 (22.8)

39 (17.9)

106 (20.7)

0.1761